|
613
|
| 3261 |
Metformin
|
NOT |
affects_activity of
|
MME
|
|
| 3262 |
Metformin
|
NOT |
affects_quantity of
|
MME
|
|
|
19237574
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,076
|
| 16741 |
MME
|
|
decreases_quantity of
|
ACTH
|
|
| 16742 |
MME
|
|
decreases_quantity of
|
Alpha-MSH
|
|
|
17363457
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,414
|
| 31851 |
APP (intracellular domain AICD)
|
|
increases_expression of
|
MME
|
via promoter-binding; depending on cell type
|
|
22122663
|
Alzheimer disease
|
|
3,430
|
| 31932 |
aging
|
|
decreases_quantity of
|
MME
|
concerning the steady-state levels; the steady-state levels of IDE and NEP are significantly higher in the cerebellum compared to the cortex and hippocampus
|
| 82499 |
aging
|
|
increases_quantity of
|
MME
|
in the cerebellum ; or remain unaltered during aging
|
|
15708439
|
Alzheimer disease
|
|
3,440
|
| 32011 |
exercise
|
|
increases_activity of
|
MME
|
|
|
22563077
|
Alzheimer disease
|
|
3,657
|
| 34793 |
Sin-1
|
NOT |
affects_activity of
|
MME
|
in vitro
|
|
22227962
|
Alzheimer disease
|
|
3,761
|
| 37258 |
MME
|
|
decreases_quantity of
|
Amyloid beta peptide
|
in type 2 microglia; by degrading Abeta
|
| 37282 |
IL4
|
|
increases_expression of
|
MME
|
|
|
22970774
|
Alzheimer disease
|
|
3,792
|
| 37833 |
aging
|
|
decreases_expression of
|
MME
|
in microglia; in older transgenic presenilin 1 (PS1)-APP mice
|
|
19464758
|
Alzheimer disease
|
|
4,090
|
| 42351 |
MME
|
|
decreases_quantity of
|
Amyloid beta peptide
|
Neprilysin is mainly localized at the pre-synaptic areas of neurons and participates in Abeta degradation.
|
| 42352 |
Somatostatin
|
|
increases_expression of
|
MME
|
at the cell membrane
|
| 42353 |
Alzheimer disease
|
|
decreases_quantity of
|
MME
|
in AD hippocampus and AD cerebral cortex
|
| 42356 |
mild cognitive impairment
|
|
decreases_quantity of
|
MME
|
in CSF
|
|
20158567
|
Alzheimer disease
|
|
4,869
|
| 48005 |
Abeta42-Al complex
|
|
decreases_expression of
|
MME
|
|
|
21298039
|
Alzheimer disease
|
|
6,360
|
| 59606 |
MME
|
|
decreases_quantity of
|
Glucagon-like peptide 1
|
|
|
15655705
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,197
|
| 82489 |
MME
|
|
decreases_quantity of
|
Amyloid beta peptide
|
|
| 82494 |
MME
|
|
interacts (colocalizes) with
|
MME
|
in lipid rafts; forming a homodimer
|
| 82522 |
APP (intracellular domain AICD)
|
|
increases_expression of
|
MME
|
|
| 83010 |
response to cholesterol depletion
|
|
decreases_expression of
|
MME
|
Cholesterol depletion in cells by MbetaCD
|
|
22737128
|
Neurological
Alzheimer disease
|
|
8,232
|
| 83169 |
APP695
|
|
increases_expression of
|
MME
|
in a gamma-secretase- and AICD-dependent manner
|
| 83175 |
BACE1
|
|
increases_expression of
|
MME
|
|
| 83178 |
APP695
|
|
increases_expression of
|
MME
|
in neuronal SH-SY5Y cells
|
| 83181 |
APP-p.KM670/671NL
|
|
increases_expression of
|
MME
|
in SH-SY5Y cells expressing the Swedish mutant of APP(695); the Swedish mutant of APP(695), compared with wild-type APP(695) cells
|
| 83182 |
response to cholesterol depletion
|
|
decreases_quantity of
|
MME
|
in cholesterol-depleted APP(695) cells
|
|
20961856
|
Alzheimer disease
|
|
8,779
|
| 91610 |
APP (intracellular domain AICD)
|
|
affects_expression of
|
MME
|
|
| 91635 |
APP695
|
|
increases_expression of
|
MME
|
in neuronal cell lines
|
| 91641 |
APP (intracellular domain AICD)
|
|
increases_expression of
|
MME
|
|
| 91646 |
Imatinib
|
|
increases_quantity of
|
MME
|
via stabilising and elevating AICD levels
|
|
23684647
|
Alzheimer disease
|
|
10,371
|
| 107582 |
MME
|
|
affects_activity of
|
Spinocerebellar ataxia 43
|
|
| 107584 |
MME
|
|
affects_activity of
|
sensorimotor axonal polyneuropathy, late-onset
|
|
| 107585 |
MME
|
|
affects_activity of
|
ataxia, cerebellar
|
|
| 124220 |
MME
|
|
affects_activity of
|
pes cavus
|
|
| 124221 |
MME
|
|
affects_activity of
|
abnormal gait
|
|
| 124222 |
MME
|
|
affects_activity of
|
hypometric saccades
|
|
| 124224 |
MME
|
|
affects_activity of
|
dysarthria
|
|
| 124225 |
MME
|
|
affects_activity of
|
cerebellar vermis atrophy
|
|
|
27583304
|
Spinocerebellar ataxia 43
|
|
10,372
|
| 107586 |
MME
|
|
affects_activity of
|
Charcot-Marie-Tooth disease, axonal, type 2T
|
|
| 124227 |
MME
|
|
affects_activity of
|
axonal neuropathy, late-onset
|
|
| 124228 |
MME
|
|
affects_activity of
|
muscle weakness
|
|
| 124229 |
MME
|
|
affects_activity of
|
muscular atrophy
|
|
| 124231 |
MME
|
|
affects_activity of
|
abnormal gait
|
|
|
26991897
|
Charcot-Marie-Tooth disease, axonal, type 2T
|
|
10,373
|
| 107587 |
heart failure
|
|
increases_activity of
|
MME
|
in cardiac muscle
|
| 107588 |
aortic valve stenosis
|
|
increases_activity of
|
MME
|
in cardiac muscle
|
|
11804980
|
Cardiovascular disease
|
|
10,825
|
| 110372 |
MME
|
|
affects_activity of
|
Myocardial infarction
|
|
|
31269974
|
Myocardial infarction
|
|
11,717
|
| 116435 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-7)
|
|
|
30404071
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,751
|
| 116385 |
MME
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116896 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116897 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
|
15283675
|
Endocrine
|
|
11,776
|
| 116584 |
MME
|
|
decreases_quantity of
|
Angiotensin I
|
|
| 116585 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
23463883
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,027
|
| 117942 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-12)
|
in renal cortical membranes
|
| 117943 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in renal cortical membranes
|
| 117944 |
MME
|
|
increases_quantity of
|
Angiotensin (1-4)
|
in renal cortical membranes
|
|
22490446
|
Cardiovascular disease
|
|
12,029
|
| 118005 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 118006 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
30934934
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,056
|
| 118348 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-9)
|
|
| 118350 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
19065996
|
Diabetes mellitus, type II
Insulin resistance
|
|
12,286
|
| 120477 |
sex, male
|
|
increases_activity of
|
MME
|
in blood serum; in younger males
|
|
28174624
|
Cardiovascular disease
|
|
12,344
|
| 120835 |
atherosclerotic lesions
|
|
increases_expression of
|
MME
|
|
|
27754866
|
Cardiovascular disease
|
|
12,867
|
| 123403 |
Progesterone
|
|
increases_expression of
|
MME
|
in human endometrium
|
| 123404 |
Estradiol
|
|
increases_expression of
|
MME
|
in uterus as well as in rat brain and a neuroblastoma cell line
|
| 123440 |
Progesterone
|
NOT |
affects_expression of
|
MME
|
concerning mRNA level
|
| 123453 |
Estradiol
|
NOT |
affects_expression of
|
MME
|
in primary neuron cultures; concerning mRNA level
|
|
22962256
|
Alzheimer disease
|
|
13,042
|
| 124235 |
Obesity
|
|
increases_quantity of
|
MME
|
|
| 124237 |
MME
|
|
affects_activity of
|
diarrhea
|
|
| 124238 |
MME
|
|
affects_activity of
|
hypertension
|
|
| 124239 |
MME
|
|
affects_activity of
|
decreased insulin sensitivity
|
|
| 124240 |
MME
|
|
affects_activity of
|
pancreatic beta cell
|
|
| 124241 |
MME
|
|
affects_activity of
|
impaired glucose tolerance
|
|
| 124243 |
MME
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
| 124245 |
MME
|
|
affects_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
| 124248 |
MME
|
|
affects_quantity of
|
Bradykinin
|
|
| 124249 |
MME
|
|
affects_quantity of
|
CCK
|
|
| 124250 |
MME
|
|
affects_quantity of
|
GIP
|
|
| 124251 |
MME
|
|
affects_quantity of
|
Glucagon-like peptide 1
|
|
| 124252 |
MME
|
|
affects_quantity of
|
NPPA
|
|
| 124253 |
MME
|
|
affects_quantity of
|
NPPB
|
|
| 124254 |
MME
|
|
affects_quantity of
|
PPY
|
|
| 124255 |
MME
|
|
affects_quantity of
|
PYY
|
|
| 124256 |
MME
|
|
affects_quantity of
|
SCT
|
|
| 124257 |
MME
|
|
affects_quantity of
|
VIP
|
|
| 124258 |
MME
|
|
affects_quantity of
|
Adrenomedullin
|
|
| 124259 |
MME
|
|
affects_quantity of
|
Angiotensin II
|
|
| 124260 |
MME
|
|
affects_quantity of
|
Angiotensin (1-7)
|
|
| 124261 |
MME
|
|
affects_quantity of
|
Endothelin-1
|
|
| 124262 |
MME
|
|
affects_quantity of
|
Glucagon
|
|
| 124263 |
MME
|
|
affects_quantity of
|
IL1B
|
|
| 124264 |
MME
|
|
affects_quantity of
|
IAPP
|
|
| 124265 |
MME
|
|
affects_quantity of
|
Somatostatin
|
|
| 124270 |
MME
|
|
increases_activity of
|
renin-angiotensin system
|
|
|
31089754
|
Diabetes mellitus, type II
Insulin resistance
Cardiomyopathy, diabetic
|
|
13,049
|
| 124273 |
MME
|
|
affects_activity of
|
Alzheimer disease
|
|
|
31266021
|
Neurodegenerative disorder
|
|
13,714
|
| 128785 |
Testosterone
|
|
affects_expression of
|
MME
|
|
| 128787 |
Testosterone
|
|
increases_expression of
|
MME
|
in neurons; through an AR-dependent mechanism which in turn decreases Abeta, upregulation of IDE and NEP may also have a beneficial effect on the levels, toxicity or fibrillization of amylin
|
| 128908 |
MME
|
|
decreases_quantity of
|
Amyloid beta peptide
|
Abeta-degrading enzyme
|
| 128911 |
SARM (NEP28)
|
|
increases_activity of
|
MME
|
probabely reducing brain Abeta levels
|
|
28655134
|
Alzheimer disease
|
CIDeRplus